Silexion Therapeutics Corp Warrant
SLXNWStock
$0.03
Market Cap—
P/E—
Div yield—
Beta-1.02
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-46.02%
Price vs S&P 500 (4W)13.01%
VGM Score18.13
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SLXNWSilexion Therapeutics Corp Warrant | — | — | F | $0.03 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Silexion Therapeutics is a clinical-stage biotechnology company focused on developing treatments for KRAS-driven cancers. Its lead candidate, SIL204, is a locally administered RNA interference therapy targeting locally advanced pancreatic cancer patients with specific KRAS mutations (G12D/G12V), used in combination with standard chemotherapy. The therapy addresses non-resectable tumors that cannot be surgically removed, representing a significant unmet medical need.